Anavex Life Sciences Corp (AVXL)

[Hosai]

Even if there is not a perfect correlation it would seem overall studies recently have tended to find an around 60-80% correlation between plasma Aß42/40 and global amyloid burden measured by PET (according to google gemini). Therefore I would says it is worth more than a "regulatory side note". It would be rather crazy for Anavex not to mention the differences with competition even if not a perfect comparison.
Mayo noted on stocktwits that it did 73% better than Lecanemab at 52 weeks and about 60% better than Lecanemab score at week 72. So this wasn't a slim impovement even if only measuring something with a 70% odd correlation.
Obv this is ignoring the other biomarker of brain volume loss reduction in blarcamesine in the dosed group vs placebo with a 5 in 10,000 chance of this being due to chance. The Mabs instead shrink the brain quicker than placebo.